CCL2 and metabolic dysfunction-associated steatohepatitis: Studies revealed that mice lacking expression of this miRNA showed an increase in lipogenesis, lower serum cholesterol/triglyceride levels, fibrosis enhancement, NASH, and hepatocellular carcinoma, in addition to increased expression of TNF‐α, IL-6, and C-C motif chemokine ligand 2 (CCL2) genes [80, 81].